Abbott Plans Phase III Study Of Potential First-In-Class Psoriasis Therapy This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Monoclonal antibody ABT-874 reduced psoriasis symptoms significantly in patients in a Phase II study, Abbott reports.
You may also be interested in...
Centocor Novel Psoriasis Biologic On Track Following Positive Phase III
Johnson & Johnson subsidiary reports positive results of a Phase III study evaluating the monoclonal antibody targeting interleukin 12 and interleukin 23.
Centocor Novel Psoriasis Biologic On Track Following Positive Phase III
Johnson & Johnson subsidiary reports positive results of a Phase III study evaluating the monoclonal antibody targeting interleukin 12 and interleukin 23.
Abbott Submits Humira sBLA for Juvenile Rheumatoid Arthritis
If approved, Humira would compete directly with Wyeth/Amgen’s Enbrel in the indication.